The Japanese encephalitis vaccine is a preventive measure against Japanese encephalitis virus (JEV), a mosquito-borne virus that can cause severe inflammation of the brain. Japanese encephalitis is prevalent in parts of Asia, where the virus is transmitted primarily by Culex mosquitoes. The vaccine is composed of inactivated JEV and stimulates the immune system to produce antibodies, providing protection against the virus. Different formulations of the vaccine exist, including live attenuated and inactivated versions, offering options for various populations and age groups. Vaccination is particularly crucial for individuals residing in or traveling to regions where Japanese encephalitis is endemic. It is recommended for travelers, expatriates, and residents in affected areas, especially during peak transmission seasons. The vaccination schedule typically involves multiple doses to ensure optimal immunity. In addition to routine immunization, catch-up vaccination campaigns may be conducted in high-risk areas.
Duccio Medini
BioForge, United States
Jocelyn Jakubik
Apex Pathogen Solutions, United States
Sergey V Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Rosane Cuber Guimaraes
Bio-Manguinhos/ Fiocruz, Brazil
Zhujun Ao
University of Manitoba, Canada
Sergey V Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Ashish Kumar Maurya
John Snow India, India
Sajal Dey
BRIC-Centre for DNA Fingerprinting and Diagnostics, India
Ayman H M El Deeb
Cairo University, EgyptSubmit your abstract Today
Title : A universal AI design framework and brokerage platform for democratised manufacturing of mRNA therapeutics
Duccio Medini, BioForge, United States
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Development of VSV-vector based vaccine against H5N1 avian influenza by targeting both H5N1 hemagglutinin and matrix protein 2
Zhujun Ao, University of Manitoba, Canada
Title : A novel responsive microneedle platform for reliable drug and vaccine delivery
Huanhuan Li, Queen’s University Belfast, United Kingdom
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : Comparative efficacy of different H9N2 avian influenza virus inactivated vaccines using some commercially available adjuvants for superior control in broilers
Ayman H M El Deeb, Cairo University, Egypt
Title : Structure-based design and development of next-generation Respiratory Syncytial Virus (RSV) vaccine
Lei Chen, Yikang Biotech Suzhou Co., Ltd, China
Title : Unmasking urban immunization inequities: A cross-sectional LQAS analysis of zero-dose drivers in slum and non-slum settings of Uttar Pradesh, India
Ashish Kumar Maurya, John Snow India, India